Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXPNASDAQ:ELYMNASDAQ:NRXPNASDAQ:RANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$0.38-1.3%$0.39$0.30▼$3.33$8.47M-1.37161,384 shs40,930 shsELYMEliem Therapeutics$1.24+4.2%$1.28$2.35▼$11.55$36.89M-0.39486,688 shs122,830 shsNRXPNRx Pharmaceuticals$2.25-2.0%$2.01$1.10▼$6.01$38.95M1.44395,731 shs97,382 shsRANIRani Therapeutics$0.52+7.1%$1.21$0.46▼$6.38$29.89M0.25775,718 shs5.29 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals-5.03%+11.41%+7.23%-48.94%-81.82%ELYMEliem Therapeutics+4.20%-2.36%-3.13%-20.00%-85.26%NRXPNRx Pharmaceuticals+10.10%+19.27%+11.71%-22.11%-23.41%RANIRani Therapeutics-21.42%-55.40%-59.52%-71.50%-92.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals2.6582 of 5 stars3.55.00.00.02.11.70.0ELYMEliem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANRXPNRx Pharmaceuticals1.8908 of 5 stars3.62.00.00.01.80.80.6RANIRani Therapeutics3.2009 of 5 stars3.63.00.00.03.31.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 3.00Buy$12.003,100.00% UpsideELYMEliem Therapeutics 0.00N/AN/AN/ANRXPNRx Pharmaceuticals 3.20Buy$28.501,169.49% UpsideRANIRani Therapeutics 3.20Buy$12.002,225.58% UpsideCurrent Analyst Ratings BreakdownLatest ACXP, NRXP, ELYM, and RANI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.004/29/2025NRXPNRx PharmaceuticalsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $46.004/3/2025RANIRani TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/2/2025NRXPNRx PharmaceuticalsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.003/31/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/24/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/20/2025NRXPNRx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.003/19/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/17/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/14/2025NRXPNRx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.002/26/2025RANIRani TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.34 per shareN/AELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/A($1.38) per shareN/ARANIRani Therapeutics$1.03M28.85N/AN/A$0.51 per share1.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.58M-$0.87N/AN/AN/AN/A-392.36%-223.78%N/AELYMEliem Therapeutics-$35.12M-$0.53N/A∞N/AN/A-47.03%-45.97%N/ANRXPNRx Pharmaceuticals-$30.15M-$2.41N/AN/AN/AN/AN/A-449.16%5/15/2025 (Estimated)RANIRani Therapeutics-$33.97M-$1.06N/AN/AN/AN/A-219.64%-56.71%5/19/2025 (Estimated)Latest ACXP, NRXP, ELYM, and RANI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025NRXPNRx Pharmaceuticals-$0.40N/AN/AN/AN/AN/A5/13/2025Q1 2025RANIRani Therapeutics-$0.22-$0.22N/A-$0.22N/A$0.20 million5/12/2025Q1 2025ACXPAcurx Pharmaceuticals-$0.14-$0.11+$0.03-$0.11N/AN/A3/31/2025Q4 2024RANIRani Therapeutics-$0.24-$0.27-$0.03-$0.27N/A$1.03 million3/17/2025Q4 2024ACXPAcurx Pharmaceuticals-$0.18-$0.16+$0.02-$0.16N/AN/A3/14/2025Q4 2024NRXPNRx Pharmaceuticals-$0.20-$0.30-$0.10-$0.77N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A1.801.80ELYMEliem TherapeuticsN/A60.4160.41NRXPNRx PharmaceuticalsN/A0.200.20RANIRani Therapeutics2.341.601.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%ELYMEliem Therapeutics69.76%NRXPNRx Pharmaceuticals4.27%RANIRani Therapeutics30.19%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals29.60%ELYMEliem Therapeutics4.70%NRXPNRx Pharmaceuticals19.00%RANIRani Therapeutics50.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals322.40 million11.99 millionOptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableNRXPNRx Pharmaceuticals217.23 million12.72 millionOptionableRANIRani Therapeutics11057.48 million26.75 millionOptionableACXP, NRXP, ELYM, and RANI HeadlinesRecent News About These CompaniesRani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate UpdateMay 13 at 4:05 PM | globenewswire.comRani Therapeutics Faces Nasdaq Compliance ChallengeMay 6, 2025 | tipranks.comRani Therapeutics (RANI) Expected to Announce Earnings on MondayMay 4, 2025 | americanbankingnews.comRani Therapeutics (RANI) Expected to Announce Quarterly Earnings on MondayApril 30, 2025 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Recommendation of "Buy" from AnalystsApril 26, 2025 | marketbeat.comStifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)April 23, 2025 | markets.businessinsider.comRani Therapeutics management to meet virtually with Lake StreetApril 17, 2025 | markets.businessinsider.comRANI: 2024 Financial ResultsApril 3, 2025 | finance.yahoo.comEarnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024April 2, 2025 | investing.comQ4 2024 Rani Therapeutics Holdings Inc Earnings CallApril 1, 2025 | finance.yahoo.comRani Therapeutics reports Q4 EPS (27c), consensus (23c)April 1, 2025 | markets.businessinsider.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comRani Therapeutics Reports 2024 Financial Results and UpdatesMarch 31, 2025 | tipranks.comRani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comRani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate UpdateMarch 31, 2025 | globenewswire.comAn Overview of Rani Therapeutics Hldgs's EarningsMarch 28, 2025 | benzinga.comStifel Nicolaus Reaffirms Their Buy Rating on Rani Therapeutics Holdings (RANI)March 28, 2025 | markets.businessinsider.comRani announces pharmacokinetic, pharmacodynamic data from RT-114 trialMarch 27, 2025 | markets.businessinsider.comRani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102March 26, 2025 | globenewswire.comRani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsMarch 25, 2025 | globenewswire.comRANI: Impressive Bioavailability for RT-116February 18, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACXP, NRXP, ELYM, and RANI Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$0.38 0.00 (-1.29%) As of 10:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Eliem Therapeutics NASDAQ:ELYM$1.24 +0.05 (+4.20%) As of 05/12/2025Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.NRx Pharmaceuticals NASDAQ:NRXP$2.24 -0.05 (-1.97%) As of 10:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.Rani Therapeutics NASDAQ:RANI$0.52 +0.03 (+7.12%) As of 10:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oklo Reaches Critical Mass, Atomic Upside Still Available U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer NVIDIA Stock Surges on Bullish News: How High Could It Climb? ON Holding Surges, Leads High-End Retailers Into Reversal D-Wave Pushes Back on Short Seller Case With Strong Earnings NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
